FDC Limited reports Q1 FY23 revenue growth of 10%

The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands

Biocon Sdn. Bhd. enters Malaysia Book of Records

The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR

Valiant Organics to start production of OAP and Pharma Intermediates

Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23

Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%

Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore

Thermo Fisher to expand dry powder media manufacturing facility in New York

With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies

Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr

Lupin is the 6th largest company in the Indian Pharmaceutical Market

Merck KGaA posts higher earnings, profits across business segments

Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million

Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery

The WAVEsystem with the WAVEcontrol 4.0 embedded

Sandu Pharmaceuticals launches Sandu Kumarvin

Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.

PIB: Quality control of Ayush drugs